The global Remicade (Infliximab) and Biosimilar market size is projected to grow from US$ 2494.5 million in 2022 to US$ 3703.9 million in 2029; it is expected to grow at a CAGR of 5.8% from 2023 to 2029.
United States market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Remicade (Infliximab) and Biosimilar players cover J & J, Pfizer, Organon and Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
The “Remicade (Infliximab) and Biosimilar Industry Forecast” looks at past sales and reviews total world Remicade (Infliximab) and Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Remicade (Infliximab) and Biosimilar sales for 2023 through 2029. With Remicade (Infliximab) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Remicade (Infliximab) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Remicade (Infliximab) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Remicade (Infliximab) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Remicade (Infliximab) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Remicade (Infliximab) and Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Remicade (Infliximab) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Remicade (Infliximab) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Brand
Biosimilar
Segmentation by application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
J & J
Pfizer
Organon
Amgen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Remicade (Infliximab) and Biosimilar market?
What factors are driving Remicade (Infliximab) and Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Remicade (Infliximab) and Biosimilar market opportunities vary by end market size?
How does Remicade (Infliximab) and Biosimilar break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Remicade (Infliximab) and Biosimilar Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Remicade (Infliximab) and Biosimilar by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Remicade (Infliximab) and Biosimilar by Country/Region, 2018, 2022 & 2029
2.2 Remicade (Infliximab) and Biosimilar Segment by Type
2.2.1 Brand
2.2.2 Biosimilar
2.3 Remicade (Infliximab) and Biosimilar Sales by Type
2.3.1 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2018-2023)
2.3.2 Global Remicade (Infliximab) and Biosimilar Revenue and Market Share by Type (2018-2023)
2.3.3 Global Remicade (Infliximab) and Biosimilar Sale Price by Type (2018-2023)
2.4 Remicade (Infliximab) and Biosimilar Segment by Application
2.4.1 Ankylosing Spondylitis
2.4.2 Rheumatoid Arthritis
2.4.3 Crohn’s Disease
2.4.4 Other
2.5 Remicade (Infliximab) and Biosimilar Sales by Application
2.5.1 Global Remicade (Infliximab) and Biosimilar Sale Market Share by Application (2018-2023)
2.5.2 Global Remicade (Infliximab) and Biosimilar Revenue and Market Share by Application (2018-2023)
2.5.3 Global Remicade (Infliximab) and Biosimilar Sale Price by Application (2018-2023)
3 Global Remicade (Infliximab) and Biosimilar by Company
3.1 Global Remicade (Infliximab) and Biosimilar Breakdown Data by Company
3.1.1 Global Remicade (Infliximab) and Biosimilar Annual Sales by Company (2018-2023)
3.1.2 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Company (2018-2023)
3.2 Global Remicade (Infliximab) and Biosimilar Annual Revenue by Company (2018-2023)
3.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Company (2018-2023)
3.2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Company (2018-2023)
3.3 Global Remicade (Infliximab) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Remicade (Infliximab) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Remicade (Infliximab) and Biosimilar Product Location Distribution
3.4.2 Players Remicade (Infliximab) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Remicade (Infliximab) and Biosimilar by Geographic Region
4.1 World Historic Remicade (Infliximab) and Biosimilar Market Size by Geographic Region (2018-2023)
4.1.1 Global Remicade (Infliximab) and Biosimilar Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Remicade (Infliximab) and Biosimilar Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Remicade (Infliximab) and Biosimilar Market Size by Country/Region (2018-2023)
4.2.1 Global Remicade (Infliximab) and Biosimilar Annual Sales by Country/Region (2018-2023)
4.2.2 Global Remicade (Infliximab) and Biosimilar Annual Revenue by Country/Region (2018-2023)
4.3 Americas Remicade (Infliximab) and Biosimilar Sales Growth
4.4 APAC Remicade (Infliximab) and Biosimilar Sales Growth
4.5 Europe Remicade (Infliximab) and Biosimilar Sales Growth
4.6 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Growth
5 Americas
5.1 Americas Remicade (Infliximab) and Biosimilar Sales by Country
5.1.1 Americas Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023)
5.1.2 Americas Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023)
5.2 Americas Remicade (Infliximab) and Biosimilar Sales by Type
5.3 Americas Remicade (Infliximab) and Biosimilar Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Remicade (Infliximab) and Biosimilar Sales by Region
6.1.1 APAC Remicade (Infliximab) and Biosimilar Sales by Region (2018-2023)
6.1.2 APAC Remicade (Infliximab) and Biosimilar Revenue by Region (2018-2023)
6.2 APAC Remicade (Infliximab) and Biosimilar Sales by Type
6.3 APAC Remicade (Infliximab) and Biosimilar Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Remicade (Infliximab) and Biosimilar by Country
7.1.1 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023)
7.1.2 Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023)
7.2 Europe Remicade (Infliximab) and Biosimilar Sales by Type
7.3 Europe Remicade (Infliximab) and Biosimilar Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Remicade (Infliximab) and Biosimilar by Country
8.1.1 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023)
8.1.2 Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023)
8.2 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales by Type
8.3 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Remicade (Infliximab) and Biosimilar
10.3 Manufacturing Process Analysis of Remicade (Infliximab) and Biosimilar
10.4 Industry Chain Structure of Remicade (Infliximab) and Biosimilar
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Remicade (Infliximab) and Biosimilar Distributors
11.3 Remicade (Infliximab) and Biosimilar Customer
12 World Forecast Review for Remicade (Infliximab) and Biosimilar by Geographic Region
12.1 Global Remicade (Infliximab) and Biosimilar Market Size Forecast by Region
12.1.1 Global Remicade (Infliximab) and Biosimilar Forecast by Region (2024-2029)
12.1.2 Global Remicade (Infliximab) and Biosimilar Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Remicade (Infliximab) and Biosimilar Forecast by Type
12.7 Global Remicade (Infliximab) and Biosimilar Forecast by Application
13 Key Players Analysis
13.1 J & J
13.1.1 J & J Company Information
13.1.2 J & J Remicade (Infliximab) and Biosimilar Product Portfolios and Specifications
13.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 J & J Main Business Overview
13.1.5 J & J Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolios and Specifications
13.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Organon
13.3.1 Organon Company Information
13.3.2 Organon Remicade (Infliximab) and Biosimilar Product Portfolios and Specifications
13.3.3 Organon Remicade (Infliximab) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Organon Main Business Overview
13.3.5 Organon Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Remicade (Infliximab) and Biosimilar Product Portfolios and Specifications
13.4.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
14 Research Findings and Conclusion
*If Applicable.